Clinical Trial Search

Primary: Percent Change in Coronary Cross Sectional Area (CSA) From Rest to That During Isometric Handgrip Exercise (IHE) — -1.70; 2.71; -0.39; 2.04 Percent change from rest…

Primary: Slope of Change From Baseline in the ALS Functional Rating Scale (ALSFRS-R) — -1.05; -1.00 Units on a Scale per Month — p=0.4807

Primary: Overall Objective Response Rate (ORR) Based on Response Evaluation Criteria in Solid Tumors and by Rustin's Criteria (RECIST) — 4; 5; 9; 4 Participants

Primary: HDL 15-HEPE — 3.7; 10.4 nmol/mmol phospholipid

Primary: Geometric Mean Titer of Anti-Chikungunya Antibodies as Measured by 50% Plaque Reduction Neutralization Test 28 Days After Last MV-CHIK Vaccination — 21.0; 19.1; 13.6…

Primary: Relative Bioavailability — 10009.0; 6075.9 (h.ng/mL)

Primary: Proportion of Subjects Achieving Greater Than 3- or 4-Fold Increases in Neutralizing Antibody Concentration (NAC) — .844; .938; .875; .906 proportion of participants

Primary: Percentage of Participants With Kaplan-Meier Curve Progression Free Survival (PFS) Constructed With an 95% Confidence Interval — 100; 82.1; 71.0 percentage of participants

Primary: Change From Baseline-2 in ADHD Symptoms to Week 4 as Assessed by the Adult Attention-Deficit Hyperactivity Disorder Rating Scale (AD HD-RS-IV) — 38.70; -21.41 score on a…

Primary: Median Progression-Free Survival (PFS) Comparison of Thalidomide Arms Versus no Thalidomide Arms — 7.6; 8.7 months

Primary: Number of Participants With Response to Rabbit Antithymocyte Globulin (Thymoglobuline) — 1; 11; 18; 3 Participants

Primary: Co-Primary Measure: a) Symptom Reduction: OMERACT-OARSI Treatment Responsiveness — 37; 38; 18; 16 Participants

Primary: Insulin Sensitivity Low Fat Diet — 6.5; 8.2; 9.8 M value (mg/kg/min

Primary: Number of Participants With Serious Adverse Events (SAEs) and Severe Adverse Events — 9; 16; 5; 8 Participants — p=0.7209

Primary: Incidence of Adverse Events — 0.756 proportion of patients